

For Immediate Release



## **New Animal Facility for uPA/SCID Mouse Model with Humanized Liver at KMT Hepatech**

**Edmonton, February 9, 2016** – KMT Hepatech, Inc. (“KMT”) is announcing the completion of relocation to a newly renovated state-of-the-art animal facility in Edmonton. The new facility has capacity for significant expansion and facilitates ongoing increase in the efficiency and quality of KMT’s services provided using company’s proprietary KMT Mouse™ (uPA+ / + / SCID mouse with stable human hepatocytes engraftment of up to 95 per cent).

With this advancement KMT Hepatech secures consistent supply of the most robust and widely used mouse model with a highly humanized liver and continues ongoing improvement of the model. After 15 years of productive operations the company provides consistent and stable high level engraftment in produced mice with a low mortality rate. KMT’s animal facility staff has an average of ten years experience with chimeric mice and unequalled expertise in providing services to clients in the pharmaceutical and biotechnology industry, as well as governmental and academic research laboratories worldwide.

“We feel privileged that the uPA/SCID chimeric mouse facilitated the evaluation of over 150 drug candidates for hepatitis C (HCV) and without doubt accelerated the development of current highly effective HCV treatment. Licensing our mouse model internationally helped to manage high demand and support clients’ needs,” says Dr. Norman Kneteman, President and CEO of the KMT Hepatech.

Starting with an initial focus on HCV efficacy studies, the company has successfully expanded its services into hepatitis B, malaria, safety/ toxicity and drug metabolism ([www.kmthepatech.com/Services.aspx](http://www.kmthepatech.com/Services.aspx)). KMT Hepatech is proud to acknowledge that years of experience with different therapeutic agents have confirmed the correlation between KMT Mouse™ results and clinical outcomes observed in humans.

**About KMT Hepatech, Inc.:** A private company providing in vivo research services utilizing proprietary platform technology of the chimeric mouse model with highly humanized liver. For the last ten years KMT Hepatech was the only company worldwide contracted by the US National Institutes of Health to provide in vivo testing of hepatitis C drug candidates.

Contact:

Dr. Svetlana Sapelnikova

KMT Hepatech, Inc.

+1 (780) 641 1917

[www.kmthepatech.com](http://www.kmthepatech.com)